Researchers with the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators have shown that immature natural killer cells are present in patients with triple-negative breast cancer and likely promote, instead of inhibit, disease progression in this cancer type.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.
